Sleep disorders in Amyotrophic Lateral Sclerosis

Authors

  • Sireesha Murala MD University of Missouri-Columbia
  • Nakul Katyal MD University of missouri
  • Naureen Narula
  • Raghav Govindarajan MD
  • Pradeep Sahota MD

DOI:

https://doi.org/10.17161/rrnmf.v2i4.15293

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting both the central and peripheral nervous system. The median survival rate for ALS patients after symptom onset is 2.5 to 3.5 years and after diagnosis of ALS is about 1.5 to 2.5 years. Patients with ALS can have a wide spectrum of sleep disorders including but not limited to insomnia, sleep related breathing disorders, parasomnias, obstructive sleep apnea (OSA) and nocturnal hypoventilation (NH). Sleep-related breathing disorders substantially increase both morbidity and mortality in ALS patients. In this review, we have discussed the ALS motor symptoms, sleep-related breathing disorders, behavioral abnormalities and sleep disturbing factors which impair the health-related quality of life.

Downloads

Download data is not yet available.

References

Boentert M. Sleep and Sleep Disruption in Amyotrophic Lateral Sclerosis. Curr Neurol Neurosci Rep. 2020;20(7):25-.

Boentert MJN, sleep so. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. 2019;11:97.

Hardiman O, Al-Chalabi A, Chio AJAlsNRDP. Corr eM, Logroscino G, Robberecht w, Shaw PJ, Simmons Z, van den Berg LH. 2017;3.

Carvalho M, Schwartz M, Swash MJM, Medicine NOJotAAoE. Involvement of the external anal sphincter in amyotrophick lateral sclerosis. 1995;18(8):848-53.

Grad LI, Rouleau GA, Ravits J, Cashman NRJCSHpim. Clinical spectrum of amyotrophic lateral sclerosis (ALS). 2017;7(8):a024117.

Alonso A, Logroscino G, Jick SS, Hernán MAJEjon. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population‐based study. 2009;16(6):745-51.

Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani RJN. Epidemiology of ALS in Italy: a 10-year prospective population-based study. 2009;72(8):725-31.

Kab S, Moisan F, Preux PM, Marin B, Elbaz A. Nationwide incidence of motor neuron disease using the French health insurance information system database. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2017;18(5-6):426-33.

Nakken O, Lindstrøm JC, Tysnes O-B, Holmøy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19(3-4):303-10.

Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. Factors predicting survival in ALS: a multicenter Italian study. 2017;264(1):54-63.

Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. 2008;79(1):33-7.

Foster LA, Salajegheh MKJTAjom. Motor neuron disease: pathophysiology, diagnosis, and management. 2019;132(1):32-7.

Group II RS, Lacomblez L, Bensimon G, Meininger V, Leigh P, Guillet PJTL. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. 1996;347(9013):1425-31.

Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration. 2017;18(sup1):49-54.

Burke T, Galvin M, Pinto-Grau M, Lonergan K, Madden C, Mays I, et al. Caregivers of patients with amyotrophic lateral sclerosis: investigating quality of life, caregiver burden, service engagement, and patient survival. 2017;264(5):898-904.

Diaz-Abad M, Buczyner JR, Venza BR, Scharf SM, Kwan JY, Lubinski B, et al. Poor sleep quality in patients with amyotrophic lateral sclerosis at the time of diagnosis. 2018;20(2):60-8.

Lo Coco D, La Bella VJEjon. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. 2012;19(5):760-3.

Diagnosis ETFo, Sclerosis: MoAL, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force. 2012;19(3):360-75.

Panda S, Gourie-Devi M, Sharma AJNI. Sleep disorders in amyotrophic lateral sclerosis: A questionnaire-based study from India. 2018;66(3):700.

Hetta J, Jansson I. Sleep in patients with amyotrophic lateral sclerosis. Journal of neurology. 1997;244(4 Suppl 1):S7-9.

Günther R, Richter N, Sauerbier A, Chaudhuri KR, Martinez-Martin P, Storch A, et al. Non-motor symptoms in patients suffering from motor neuron diseases. 2016;7:117.

Skapinakis P, Rai D, Anagnostopoulos F, Harrison S, Araya R, Lewis GJPM. Sleep disturbances and depressive symptoms: an investigation of their longitudinal association in a representative sample of the UK general population. 2013;43(2):329-39.

Montagna P, Liguori R, Zucconi M, Lugaresi A, Cirignotta F, Lugaresi E. Fasciculations during wakefulness and sleep. Acta neurologica Scandinavica. 1987;76(2):152-4.

Lo Coco D, Mattaliano P, Spataro R, Mattaliano A, La Bella V. Sleep-wake disturbances in patients with amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry. 2011;82(8):839-42.

Stephens HE, Joyce NC, Oskarsson BJALS, Degeneration F. National study of muscle cramps in ALS in the USA. 2017;18(1-2):32-6.

Caress JB, Ciarlone SL, Sullivan EA, Griffin LP, Cartwright MSJM, nerve. Natural history of muscle cramps in amyotrophic lateral sclerosis. 2016;53(4):513-7.

Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau‐Pazos M, Parziale N, et al. Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double‐blind crossover trial. 2018;58(1):42-8.

Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease. The Cochrane database of systematic reviews. 2012(4):Cd004157.

Hogan DBJC. Quinine: not a safe drug for treating nocturnal leg cramps. 2015;187(4):237-8.

Hayashi T, Narita Y, Okugawa N, Hamaguchi E, Shibahara M, Kuzuhara SJALS. Pressure ulcers in ALS patients on admission at a university hospital in Japan. 2007;8(5):310-3.

Högl B, Kiechl S, Willeit J, Saletu M, Frauscher B, Seppi K, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. 2005;64(11):1920-4.

Lo Coco D, Piccoli F, La Bella V. Restless legs syndrome in patients with amyotrophic lateral sclerosis. Movement disorders : official journal of the Movement Disorder Society. 2010;25(15):2658-61.

Dalla Bella E, Lombardi R, Porretta‐Serapiglia C, Ciano C, Gellera C, Pensato V, et al. Amyotrophic lateral sclerosis causes small fiber pathology. 2016;23(2):416-20.

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. 2016;21:1-11.

Bara-Jimenez W, Aksu M, Graham B, Sato S, Hallett MJN. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. 2000;54(8):1609-16.

Lo Coco D, Puligheddu M, Mattaliano P, Congiu P, Borghero G, Fantini ML, et al. REM sleep behavior disorder and periodic leg movements during sleep in ALS. Acta neurologica Scandinavica. 2017;135(2):219-24.

Boentert M, Glatz C, Helmle C, Okegwo A, Young PJJoN, Neurosurgery, Psychiatry. Prevalence of sleep apnoea and capnographic detection of nocturnal hypoventilation in amyotrophic lateral sclerosis. 2018;89(4):418-24.

Cheatle MD, Foster S, Pinkett A, Lesneski M, Qu D, Dhingra L. Assessing and Managing Sleep Disturbance in Patients with Chronic Pain. Anesthesiology clinics. 2016;34(2):379-93.

Ganzini L, Silveira MJ, Johnston WSJJop, management s. Predictors and correlates of interest in assisted suicide in the final month of life among ALS patients in Oregon and Washington. 2002;24(3):312-7.

Ahmed RM, Newcombe RE, Piper AJ, Lewis SJ, Yee BJ, Kiernan MC, et al. Sleep disorders and respiratory function in amyotrophic lateral sclerosis. 2016;26:33-42.

Braun AT, Caballero-Eraso C, Lechtzin NJCicm. Amyotrophic lateral sclerosis and the respiratory system. 2018;39(2):391-400.

Quaranta VN, Carratu P, Damiani MF, Dragonieri S, Capozzolo A, Cassano A, et al. The prognostic role of obstructive sleep apnea at the onset of amyotrophic lateral sclerosis. 2017;17(1):14-21.

Berger KI, Rapoport DM, Ayappa I, Goldring RMJSMC. Pathophysiology of hypoventilation during sleep. 2014;9(3):289-300.

Boentert M, Brenscheidt I, Glatz C, Young PJJon. Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis. 2015;262(9):2073-82.

Vrijsen B, Buyse B, Belge C, Robberecht W, Van Damme P, Decramer M, et al. Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study. 2015;11(5):559-66.

Ogna A, Salva M-AQ, Prigent H, Mroue G, Vaugier I, Annane D, et al. Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature. 2016;20(2):575-81.

Carratù P, Cassano A, Gadaleta F, Tedone M, Dongiovanni S, Fanfulla F, et al. Association between low sniff nasal-inspiratory pressure (SNIP) and sleep disordered breathing in amyotrophic lateral sclerosis: preliminary results. 2011;12(6):458-63.

Tilanus T, Groothuis J, TenBroek-Pastoor J, Feuth T, Heijdra Y, Slenders J, et al. The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis. 2017;18(1):144.

Ackrivo J, Hansen-Flaschen J, Wileyto EP, Schwab RJ, Elman L, Kawut SMJERJ. Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis. 2019;53(4).

Bote SM, Martinez NP, Amarilla CE, Ugalde PF, Gonzalez-Bermejo J, Collado NF, et al. Overnight pulse oximetry to determine prognostic factors in subjects with amyotrophic lateral sclerosis. 2020.

Bertella E, Banfi P, Paneroni M, Grilli S, Bianchi L, Volpato E, et al. Early initiation of night-time NIV in an outpatient setting: a randomized non-inferiority study in ALS patients. 2017;53(6):892-9.

Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber MJPO. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. 2017;12(5):e0177555.

Elamin EM, Wilson CS, Sriaroon C, Crudup B, Pothen S, Kang YC, et al. Effects of early introduction of non‐invasive positive pressure ventilation based on forced vital capacity rate of change: Variation across amyotrophic lateral sclerosis clinical phenotypes. 2019;73(1):e13257.

Sivori M, Rodriguez GE, Pascansky D, Saenz C, Sica REJM-BA-. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. 2007;67(4):326.

Vandoorne E, Vrijsen B, Belge C, Testelmans D, Buyse BJACB. Noninvasive ventilation in amyotrophic lateral sclerosis: effects on sleep quality and quality of life. 2016;71(6):389-94.

Vitacca M, Montini A, Lunetta C, Banfi P, Bertella E, De Mattia E, et al. Impact of an early respiratory care programme with non‐invasive ventilation adaptation in patients with amyotrophic lateral sclerosis. 2018;25(3):556-e33.

Sancho J, Burés E, Ferrer S, Ferrando A, Bañuls P, Servera EJEor. Unstable control of breathing can lead to ineffective noninvasive ventilation in amyotrophic lateral sclerosis. 2019;5(3).

Teschler H, Stampa J, Ragette R, Konietzko N, Berthon-Jones MJERJ. Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. 1999;14(6):1251-7.

Georges M, Attali V, Golmard JL, Morélot-Panzini C, Crevier-Buchman L, Collet J-M, et al. Reduced survival in patients with ALS with upper airway obstructive events on non-invasive ventilation. 2016;87(10):1045-50.

Ogna A, Nardi J, Prigent H, Quera Salva M-A, Chaffaut C, Lamothe L, et al. Prognostic value of initial assessment of residual hypoventilation using nocturnal capnography in mechanically ventilated neuromuscular patients: a 5-Year follow-up study. 2016;3:40.

Sancho J, Servera E, Morelot-Panzini C, Salachas F, Similowski T, Gonzalez-Bermejo JJALS, et al. Non-invasive ventilation effectiveness and the effect of ventilatory mode on survival in ALS patients. 2014;15(1-2):55-61.

Vitacca M, Paneroni M, Trainini D, Bianchi L, Assoni G, Saleri M, et al. At home and on demand mechanical cough assistance program for patients with amyotrophic lateral sclerosis. 2010;89(5):401-6.

American Academy of Sleep Medicine %J Westchester IAAoSM. International Classification of Sleep Disorders—Third Edition (ICSD-3) Online Version. 2014.

Luppi PH, Clément O, Sapin E, Gervasoni D, Peyron C, Léger L, et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep medicine reviews. 2011;15(3):153-63.

Boeve B, Silber M, Ferman T, Lin S-C, Benarroch E, Schmeichel A, et al. Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder±a Coexisting Neurologic Disorder (PL01. 003). AAN Enterprises; 2013.

Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. 2014;9(2):e89741.

Jung Y, Louis EKSJCtoin. Treatment of REM sleep behavior disorder. 2016;18(11):50.

Congiu P, Mariani S, Milioli G, Parrino L, Tamburrino L, Borghero G, et al. Sleep cardiac dysautonomia and EEG oscillations in amyotrophic lateral sclerosis. 2019;42(11):zsz164.

Downloads

Published

2021-09-17

How to Cite

Murala, S., Katyal, N., Narula, N., Govindarajan, R., & Sahota, P. (2021). Sleep disorders in Amyotrophic Lateral Sclerosis . RRNMF Neuromuscular Journal, 2(4). https://doi.org/10.17161/rrnmf.v2i4.15293

Issue

Section

Looking Back and Looking Forward at Stuff (Reviews)